References
- Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579:265–269.
- Deng S-Q, Peng H-J. Characteristics of and public health responses to the coronavirus disease 2019 outbreak in China. J Clin Med. 2020;9:575.
- Hu B, Guo H, Zhou P, et al. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2020;19:1–14.
- Han Q, Lin Q, Jin S, et al. Coronavirus 2019-nCoV: a brief perspective from the front line. J Infect. 2020;80:373–377.
- Velavan TP, Meyer CG. The COVID-19 epidemic. Trop Med Int Health. 2020;25:278–280.
- Murthy S, Gomersall CD, Fowler RA. Care for critically ill patients with COVID-19. J Am Med Assoc. 2020;323:1499–1500.
- Bikdeli B, Madhavan M V, Jimenez D, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75:2950–2973.
- FDA. COVID-19 vaccines; 2021. Available from: https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines
- Zhou D, Dai SM, Tong Q. COVID-19: A recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. J Antimicrob Chemother. 2020;75:1667–1670.
- Viveiros Rosa SG, Santos WC. Clinical trials on drug repositioning for COVID-19 treatment. Rev Panam Salud Publica. 2020;44:e40.
- Caly L, Druce JD, Catton MG, et al. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020;178:104787.
- Campbell WC. Ivermectin: an update. Parasitol Today. 1985;1:10–16.
- Pitterna T, Cassayre J, Hüter OF, et al. New ventures in the chemistry of avermectins. Bioorg Med Chem. 2009;17:4085–4095.
- Canga AG, Prieto AMS, Diez Liébana MJ, et al. The pharmacokinetics and interactions of ivermectin in humans – a mini-review. AAPS J. 2008;10:42–46.
- Tay MYF, Fraser JE, Chan WKK, et al. Nuclear localization of dengue virus (DENV) 1-4 non-structural protein 5; protection against all 4 DENV serotypes by the inhibitor ivermectin. Antiviral Res. 2013;99:301–306.
- Wagstaff KM, Sivakumaran H, Heaton SM, et al. Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus. Biochem J. 2012;443:851–856.
- Yang SNY, Atkinson SC, Wang C, et al. The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer. Antiviral Res. 2020;177:104760.
- Lott K, Cingolani G. The importin β binding domain as a master regulator of nucleocytoplasmic transport. Biochim Biophys Acta – Mol Cell Res. 2011;1813:1578–1592.
- Kau TR, Way JC, Silver PA. Nuclear transport and cancer: from mechanism to intervention. Nat Rev Cancer. 2004;4:106–117.
- Bikadi Z, Hazai E. Application of the PM6 semi-empirical method to modeling proteins enhances docking accuracy of AutoDock. J Cheminform. 2009;1:15.
- Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2009;31:455–461.
- Jones G, Willett P, Glen RC, et al. Development and validation of a genetic algorithm for flexible docking. J Mol Biol. 1997;267:727–748.
- Park S, Khalili-Araghi F, Tajkhorshid E, et al. Free energy calculation from steered molecular dynamics simulations using Jarzynski’s equality. J Chem Phys. 2003;119:3559–3566.
- Krieger E, Dunbrack RL, Hooft RWW, et al. Assignment of protonation states in proteins and ligands: combining pK a prediction with hydrogen bonding network optimization. Methods Mol Biol. 2012;819:405–421.
- Dickson CJ, Madej BD, Skjevik ÅA, et al. Lipid14: the amber lipid force field. J Chem Theory Comput. 2014;10:865–879.
- Wong CF. Steered molecular dynamics simulations for uncovering the molecular mechanisms of drug dissociation and for drug screening: a test on the focal adhesion kinase. J Comput Chem. 2018;39:1307–1318.
- Krieger E, Nielsen JE, Spronk CAEM, et al. Fast empirical pKa prediction by Ewald summation. J Mol Graph Model. 2006;25:481–486.
- Krieger E, Vriend G. New ways to boost molecular dynamics simulations. J Comput Chem. 2015;36:996–1007.
- Elfiky AA, Azzam EB. Novel guanosine derivatives against MERS CoV polymerase: An in silico perspective. J Biomol Struct Dyn. 2021;39:2923–2931.
- Enayatkhani M, Hasaniazad M, Faezi S, et al. Reverse vaccinology approach to design a novel multi-epitope vaccine candidate against COVID-19: an in silico study. J Biomol Struct Dyn. 2021;39:2857–2872.
- Muralidharan N, Sakthivel R, Velmurugan D, et al. Computational studies of drug repurposing and synergism of lopinavir, oseltamivir and ritonavir binding with SARS-CoV-2 protease against COVID-19. J Biomol Struct Dyn. 2021;39:2673–2678.
- Al Mamun A, Akter F, Khan M, et al. Identification of potent inhibitors against transmembrane serine protease 2 for developing therapeutics against SARS-CoV-2. J Biomol Struct Dyn. 2021:1–13. DOI:https://doi.org/10.1080/07391102.2021.1980109
- Efaz F, Islam S, Talukder SA, et al. Repurposing fusion inhibitor peptide against SARS-CoV-2. J Comput Chem. 2021. DOI:https://doi.org/10.1002/jcc.26758
- Sakib MMH, Nishat AA, Islam MT, et al. Computational screening of 645 antiviral peptides against the receptor-binding domain of the spike protein in SARS-CoV-2. Comput Biol Med. 2021;136:104759. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0010482521005539
- Chowdhury SM, Talukder SA, Khan AM, et al. Antiviral peptides as promising therapeutics against SARS-CoV-2. J Phys Chem B. 2020;124:9785–9792. Available from: https://pubs.acs.org/doi/10.1021/acs.jpcb.0c05621
- Forlemu N, Watkins P, Sloop J. Molecular docking of selective binding affinity of sulfonamide derivatives as potential antimalarial agents targeting the glycolytic enzymes: GAPDH, aldolase and TPI. Open J Biophys. 2017;07:41–57.
- Kumari R, Kumar R, Lynn A. G-mmpbsa – a GROMACS tool for high-throughput MM-PBSA calculations. J Chem Inf Model. 2014;54:1951–1962.
- Cheng P, Li J, Wang J, et al. Investigations of FAK inhibitors: a combination of 3D-QSAR, docking, and molecular dynamics simulations studies. J Biomol Struct Dyn. 2018;36:1529–1549.
- Kumar H, Raj U, Gupta S, et al. In-silico identification of inhibitors against mutated BCR-ABL protein of chronic myeloid leukemia: a virtual screening and molecular dynamics simulation study. J Biomol Struct Dyn. 2016;34:2171–2183.
- Fuglebakk E, Echave J, Reuter N. Measuring and comparing structural fluctuation patterns in large protein datasets. Bioinformatics. 2012;28:2431–2440.
- Liu X, Jing Z, Jia WQ, et al. Identification of novel PPARα/γ dual agonists by virtual screening, ADMET prediction and molecular dynamics simulations. J Biomol Struct Dyn. 2018;36:2988–3002.